



**For Immediate Release:**

Wednesday, October 26, 2011

**Contact:**

Grace Schroer (301) 215-9099  
gschroer@bcan.org

**Two New Directors Elected to Serve on the Bladder Cancer Advocacy Network Board**

***William Shipley, MD, Professor of Radiation Oncology at Harvard Medical School  
and Robert Levin, MBA, former Chief Business Officer at Fannie Mae,  
join the Bladder Cancer Advocacy Network Board of Directors***

Bethesda, Maryland – The Bladder Cancer Advocacy Network (BCAN), the first national advocacy organization dedicated to advancing bladder cancer research and public awareness, announced today that two new directors have been elected to serve on its board. Robert Levin, MBA and William Shipley, MD will join BCAN’s seven current directors.

BCAN co-founder and board president Diane Zipursky Quale said, “We are all honored to welcome Rob and Bill to our board. They are deeply committed to BCAN’s mission, and I am excited to see how their experiences and perspectives will help shape BCAN’s growth in the coming years.”

Robert Levin brings extensive experience to the BCAN board. Mr. Levin is currently on the board of Ellie Mae, a public company, and serves on its Audit Committee and Nominating and Corporate Governance Committee. He is also on the board of Morehouse College, serves on its Investment and Compensation Committees, and is Treasurer and Chair of the Finance Committee. Previously, Mr. Levin worked 28 years at Fannie Mae holding many positions including EVP for Housing and Community Development, Interim Chief Financial Officer, and Chief Business officer. He currently consults for a Washington, DC area real estate investment company.

Dr. William Shipley joins the BCAN board with a strong background in the breadth of issues facing bladder cancer patients and the bladder cancer research community. Dr. Shipley is the Andres Soriano Professor of Radiation Oncology at Harvard Medical School and the Head of Genitourinary Oncology at Massachusetts General Hospital. He has been a leader in clinical research in the area of genitourinary oncology for more than 35 years. Dr. Shipley’s work in bladder cancer has included implementing protocols for selected muscle-invasive bladder cancer patients which made it possible to treat over two thirds of the patients without removing their bladders. This multi-modal treatment approach combined surgical removal of the tumors, chemotherapy, and radiation.

The Bladder Cancer Advocacy Network was created in May 2005 as the first national non-profit patient-based advocacy organization for bladder cancer. BCAN’s mission is to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community.

For more information, please visit the BCAN web site at [www.bcan.org](http://www.bcan.org) or call 888-901-BCAN.